Global Big Pharma Partnering Terms and Agreements 2016-2023

$3,995.00

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals

Publication date
March 2023
Number of pages
2000+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP1010

Global Big Pharma Partnering Terms and Agreements 2016 to 2023 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

 

This report provides details of the latest Big Pharma agreements announced in the life sciences since 2016.

 

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

 

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

 

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

 

One of the key highlights of the report is that over 3,500 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

 

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2016, including details of headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Big Pharma deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.

 

Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2016. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2016.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

 

Key benefits

 

Global Big Pharma Partnering Terms and Agreements 2016 to 2023 provides the reader with the following key benefits:

 

  • In-depth understanding of Big Pharma deal trends since 2016
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
  • Identify most active Big Pharma dealmakers since 2016
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Big Pharma Partnering Terms and Agreements 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.

 

Big Pharma Partnering Terms and Agreements includes:

       

  • Trends in Big Pharma dealmaking in the biopharma industry since 2016
  • Access to headline, upfront, milestone and royalty data
  • Access to Big Pharma contract documents
  • Leading Big Pharma deals by value since 2016
  • Most active Big Pharma dealmakers since 2016

 

In Global Big Pharma Partnering Terms and Agreements 2016 to 2023, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Big Pharma Partnering Terms and Agreements 2016 to 2023 report provides comprehensive access to available deals and contract documents for over 3,500 Big Pharma deals.

 

Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Big Pharma Partnering Terms and Agreements 2016 to 2023 provides the reader with the following key benefits:

 

  • In-depth understanding of Big Pharma deal trends since 2016
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
  • Identify most active Big Pharma dealmakers since 2016
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Big Pharma dealmaking

 

2.1. Introduction

2.2. Big Pharma partnering over the years

2.3. Most active Big Pharma dealmakers

2.4. Big Pharma partnering by deal type

2.5. Big Pharma partnering by therapy area

2.6. Big Pharma partnering by technology type

2.7. Deal terms for Big Pharma partnering

2.7.1 Big Pharma partnering headline values

2.7.2 Big Pharma deal upfront payments

2.7.3 Big Pharma deal milestone payments

2.7.4 Big Pharma royalty rates

 

Chapter 3 – Leading Big Pharma deals

 

3.1. Introduction

3.2. Top Big Pharma deals by value

 

Chapter 4 – Most active Big Pharma dealmakers

 

4.1. Introduction

4.2. Most active Big Pharma dealmakers

4.3. Most active Big Pharma partnering company profiles

Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others

 

Chapter 5 – Big Pharma contracts dealmaking directory

 

5.1. Introduction

5.2. Big Pharma contracts dealmaking directory

 

Chapter 6 – Big Pharma dealmaking by technology type

 

Appendices

 

Appendix 1 – Big Pharma deals by company A-Z

Appendix 2 – Big Pharma deals by stage of development

Appendix 3 – Big Pharma deals by deal type

Appendix 4 – Big Pharma deals by therapy area

Appendix 5 – Deal type definitions

Appendix 6 – Further reading on dealmaking

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Big Pharma partnering since 2016
Figure 2: Active Big Pharma dealmaking activity– 2016 to 2023
Figure 3: Big Pharma partnering by deal type since 2016
Figure 4: Big Pharma partnering by disease type since 2016
Figure 5: Big Pharma partnering by technology type since 2016
Figure 6: Big Pharma deals with a headline value
Figure 7: Big Pharma deals with an upfront value
Figure 8: Big Pharma deals with a milestone value
Figure 9: Big Pharma deals with a royalty rate value
Figure 10: Top Big Pharma deals by value since 2016
Figure 11: Most active Big Pharma dealmakers 2016 to 2023

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1QBit, 2seventy bio, 3B Pharmaceuticals, 3SBio, 3T Biosciences, 4D Molecular Therapeutics, 4D Pharma, 4Living Biotech, 7 Hills Pharma, 23andMe, 111, 908 Devices, A*STAR Agency for Science, Technology and Research, A*STAR Singapore Immunology Network, A2 Biotherapeutics, Aarhus University Hospital, Abarca, AB Biosciences, Abbisko Therapeutics, Abbott Laboratories, Abbott Medical Optics, Abbott Vascular Devices, Abbvie, Abcam, AbCellera Biologics, Ab E Discovery, Abexxa Biologics, Abide Therapeutics, Abilita Bio, Abingworth Management, Ab Initio, Abiomed, Abionic, ABL Bio, Ablexis, Ablynx, AbMed, Abpro, Abramson Cancer Center, AbSci, Absorption Systems, Academic Drug Discovery Consortium, Acceleron Pharma, Accent Therapeutics, Accenture, Access to Comprehensive Genomic Profiling Coalition, Accord, Accumulus Synergy, Acentrus Specialty, Acer Therapeutics, Acetylon Pharmaceuticals, AC Immune, Acino Pharma, Aclaris Therapeutics, ACMG Foundation for Genetic and Genomic Medicine, Acorda Therapeutics, Acrivon Therapeutics, Actavis (acquired by Watson), Actelion, ACT Genomics, Actinium Pharmaceuticals, Acuitas Therapeutics, Acura Pharmaceuticals, Adagene, Ada Health, Adamas Pharmaceuticals, Adamis Pharmaceuticals, Adaptate Biotherapeutics, Adaptimmune, Adaptive Biotechnologies, ADC Therapeutics, Adge Pharmaceuticals, Adimab, Adlai Nortye, ADMA Biologics, AdoRx Therapeutics, Adrestia, Aduro BioTech, Advanced Accelerator Applications, Advanz Pharma, Advaxis, Advent International, Advocate Health Care, Aeglea BioTherapeutics, Aelix Therapeutics, Aerie Pharmaceuticals, AEterna Zentaris, Aetion, Aevi Genomic Medicine, AffaMed Therapeutics, Affilogic, Affimed Therapeutics, Affinivax, AGC Asahi Glass, AGC Biologics, Age Labs, Agenus Bio, AgeX Therapeutics, Agios Pharmaceuticals, AgNovos Healthcare, AgomAb Therapeutics, AgonOx, AIDS Foundation of Chicago, Aileron Therapeutics, AIM ImmunoTech, AIMM Therapeutics, Aimmune Therapeutics, AIon Labs, Ajinomoto Bio-Pharma Services, Akarna Therapeutics, Akcea Therapeutics, Akebia Therapeutics, Akero Therapeutics, Akili Interactive Labs, Akouos, Akoya Biosciences, Albany Molecular Research, Albireo, Albumedix, Alchemab, Alcon Laboratories, Alcyone Lifesciences, Alcyone Therapeutics, Alder Biopharmaceuticals, Aldeyra Therapeutics, Alector, Alectos Therapeutics, Alexion Pharmaceuticals, Alex Therapeutics, Alexza Pharmaceuticals, Aligos Therapeutics, AlivaMab Discovery Services, AliveCor, AliveGen, Alivio Therapeutics, ALK-Abello, Alkermes, Allele Biotechnology and Pharmaceuticals, Allergan, Alliance For Clinical Trials In Oncology, Alliance for Regenerative Medicine, Alliance Pharma, Allm, Allogene Therapeutics, Almac Group, Almirall, Alnylam Pharmaceuticals, Alphamab Biopharmaceuticals, Alpine Immune Sciences, Altavant Sciences, Alteogen, Altoida, Altor BioScience, Altos Group, Alveo Technologies, Alvotech, ALX Oncology, Alydia Health, Alzheimer's Drug Discovery Foundation, AM-Pharma, Amag Pharmaceuticals, Amalgam Rx, Amal Therapeutics, Amathus Therapeutics, Amazon Web Services, Amblyotech, Ambys Medicines, American Cancer Society, American College of Cardiology, American Liver Foundation, American Migraine Foundation, American Society for Parenteral and Enteral Nutrition, American Society of Gene and Cell Therapy, American Society of Hematology, Amgen, Amgros, Amicus Therapeutics, Amneal Pharmaceuticals, Amorsa Therapeutics, Amoy Diagnostics, Amphista Therapeutics, Amplyx Pharmaceuticals, AMRA Medical, Amunix, Amygdala Neurosciences, Amyris, AnaBios, Anacor Pharmaceuticals, Anaeropharma, Anavex Life Sciences, AnchorDx, Anda, Angelini Pharma, AnHeart Therapeutics, Anima Biotech, ANI Pharmaceuticals, Anji Pharma, Ankyra Therapeutics, Anokion, Anpac Bio-Medical Science, ANP Technologies, Antares Pharma, Antengene, Anterios, Anthos Therapeutics, Antigen Express, Anumana, Apexigen, Apollo Therapeutics, Apotex, Apple, Applied BioMath, Applied DNA Sciences, AprilBio, APRINOIA Therapeutics, Aptevo Therapeutics, Aptinyx, APT Therapeutics, Aqemia, Aquestive Therapeutics, Aquinnah Pharmaceuticals, Aquinox Pharmaceuticals, Aragen Life Sciences, Aralez Pharmaceuticals, Arcadia Consumer Healthcare, ArcherDX, Arch Oncology, Arctos Medical, Arcturus Therapeutics, Arcus Biosciences, Arcutis Biotherapeutics, Ardelyx, Arecor, Arena Pharmaceuticals, Argentum Pharmaceuticals, argenx, Ariad Pharmaceuticals, Aridis Pharmaceuticals, ArisGlobal, Aris Global, Aristea Therapeutics, Arixa Pharmaceuticals, Arix Bioscience, Ark Biosciences, Arrakis Therapeutics, Array Biopharma, Arrowhead Pharmaceuticals, Arrow Pharmaceuticals, Arsenal Biosciences, Artios Pharma, Artisan Bio, Artiva Biotherapeutics, Arvinas, Asahi Kasei, Asahi Kasei Pharma America, Ascentage Pharma, Ascletis, Asher Biotherapeutics, ASKA Pharmaceuticals, Asklepios Biopharmaceutical, Aspen Global, Aspen Holding, Aspen Pharmacare Canada, Assembly Biosciences, Assertio Therapeutics, Astellas Institute for Regenerative Medicine, Astellas Pharma, Astellas Pharma Europe, Astellas Pharma US, Astellas Venture Management, Astex Pharmaceuticals, AstraZeneca, Atalanta Therapeutics, Atara Biotherapeutics, AtCor Medical, Atea Pharmaceuticals, Athenex, Atnahs Pharma, Atomwise, Atreca, ATUM, Audentes Therapeutics, AUM Biosciences, Aurinia Pharmaceuticals, Aurobindo Pharma, Auspex Pharmaceuticals, Autifony Therapeutics, Autigen, Autobahn Therapeutics, Avalere Health, AvantGen, Avara Pharmaceutical Services, AVEO Oncology, Avidity Biosciences, Avillion, Avista Therapeutics, Avitide, Avricore Health, Axiom Worldwide, Axsome Therapeutics, Ayala Pharmaceuticals, Azanta, Azitra, Back-A-Line, Bactevo, Baergic Bio, Baidu, Baili Biopharmaceutical, Bain Capital, Bamboo Therapeutics, Bank of America, Banner Alzheimer's Institute, Banyan Biomarkers, Basilea Pharmaceutica, Bausch & Lomb, Bausch Health Companies, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer Animal Health, Bayer CropScience, Bayer Healthcare, Baylor College of Medicine, BC Cancer Agency, BDD Pharma, Beacon Discovery, Beam Therapeutics, Becton Dickinson, BehaVR, Beiersdorf, BeiGene, Beijing InnoCare Pharma, Beijing Strong Biotechnologies, Belharra Therapeutics, BenevolentAI, BE Pharmaceuticals, Berg, BerGenBio, Berkeley Lights, Berlin Chemie, Beryllium Discovery, Beth Israel Deaconess Medical Center, Bicycle Therapeutics, Bigfoot Biomedical, BigHat Biosciences, Bill and Melinda Gates Foundation, Bio-Techne, Bio-Thera Solutions, BioAge Labs, BioArctic Neuroscience, biOasis Technologies, BioAtla, BioCardia, Biocartis, Biocon, BIOCORP, BioCurate, Biocytogen, BioDelivery Sciences, Biofourmis, Biogen, Bioharmony Therapeutics, Biohaven Pharmaceuticals, BioInvent, BioLabs, BioLamina, BiolineRX, BiologIC Technologies, Biolojic Design, BioLum Sciences, BioMark Diagnostics, Biomedical Advanced Research and Development Authority, BIOMEDX Group, BioMed X Innovation Center, bioMerieux, BioMotiv, Biomunex Pharmaceuticals, BiomX, Bioncotech Therapeutics, Biond Biologics, Bioniz Therapeutics, BioNTech, BioPharma Plasma, Bio Products Laboratory, BioQ Pharma, BioRap Technologies, BioReference Laboratories, BioSerenity, BioSurfaces, Biotest, Biothera Pharmaceuticals, Biotoscana Farma, Biovac, Bioverativ, BioXcel, Blackford, Blackford Analysis, Blacksmith Medicines, Blackstone, Bleeding Disorders Foundation, Bluebird Bio, BlueJay Therapeutics, Blue Mesa Health, Blueprint Medicines, BMG Pharmaceuticals, BMV Medica, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Bolden Therapeutics, Bolt Biotherapeutics, Bone Therapeutics, Bora Pharmaceuticals, Boston Biomedical, Boston Pharmaceuticals, Boston University School of Medicine, BPL Medical Technologies, Brainomix, Brain Research Through Advancing Innovative NeurotechnologiesInitiative, Breast Cancer Research Foundation (BCRF), BridgeBio Pharma, Bridge Biotherapeutics, BridGene Biosciences, Bridgewest Group, Brigham and Women's Hospital, BrightInsight, Bristol-Myers Squibb, Bristol-Myers Squibb Foundation, Bristol-Myers Squibb Pakistan, Broad Institute, Burning Rock, Bushu Pharmaceuticals, Butantan Institute, BWXT Medical, C4 Therapeutics, C4X Discovery, Cadent, Cadent Therapeutics, Caladrius Biosciences, California Institute for Biomedical Research, Calithera Biosciences, Cambrex, Cambrian Biopharma, CamDiab, Camena Bioscience, CAMP4 Therapeutics, Canadian Blood Services, Canadian Cancer Society, Canadian National Transplant Research Program, CANbridge Pharmaceuticals, Cancer Research Institute, Cancer Research Society, Cancer Research UK, Candel Therapeutics, Captor Therapeutics, Cara Care, Cara Therapeutics, Caraway Therapeutics, Cardiff Oncology, Cardiome Pharma, Cardiovascular Systems, Cardurion Pharmaceuticals, Care Access Research, Carepay, Caribou Biosciences, Caris Life Sciences, Carisma Therapeutics, Carmine Therapeutics, Carmot Therapeutics, Carna BioSciences, Carrick Therapeutics, CARsgen, Casebia Therapeutics, CASI Pharmaceuticals, Casper Pharma, Cassiopea, Catalent, Catalyst Biosciences, Catalyst Pharmaceuticals, CCT Research, CDR-Life, Cedar Clinical Research, Cedars-Sinai Medical Center, Celcuity, CelerisTx, Celgene, Cell Cure Neurosciences, Cellectis, CELLINK, Cell Mogrify, CellSight Technologies, Celltech, Cell Therapy, Celltrion, Cellular Biomedicine, Celmatix, Celsius Therapeutics, Cend Therapeutics, Center for Human Genetics and Laboratory Medicine, Centogene, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Drug Research and Development (CDRD), Centrexion, Century Therapeutics, Cerecor, Cerevance, Cerevel Therapeutics, Certara, Cerulean Pharma, Cerveau Technologies, Cevec Pharmaceuticals, CG Oncology, Champions Oncology, Charles River Laboratories, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chembio Diagnostics, ChemDiv, Chemical Abstracts Service (CAS), ChemoCentryx, Cheplapharm Arzneimittel, Chi-Med, Chiesi Farmaceutici, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's National Hospital, China Medical System, China Southeast University, Chinese Academy of Sciences, Chinook Therapeutics, CHO Plus, Chronolife, Chronos Therapeutics, Chugai Pharmaceutical, Chugai Pharma Marketing, Cidara Therapeutics, Cilag AG, CinCor Pharma, Cinven, Cipla, Circassia, Circle Pharma, Circuit Therapeutics, Citius Pharmaceuticals, City of Hope, CiVi Biopharma, Claris Injectables, Claris Lifesciences, Clear Creek Bio, ClearPath, Clementia Pharmaceuticals, Click Therapeutics, Clinigen, Clinton Health Access Initiative, Cloud Pharmaceuticals, Clover Biopharmaceuticals, Clover Therapeutics, Clovis Oncology, CMC Biologics, Coala Life, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Cocrystal Pharma, Code Biotherapeutics, Codex DNA, Codexis, Cognition Kit, CogState, Coherus Biosciences, Cold Genesys, CoLucid Pharmaceuticals, Columbia University, Columbia University Medical Center, Comera Life Sciences, Compact Imaging, Compass Therapeutics, Complix, Compugen, Conatus Pharmaceuticals, ConcertAI, Concr, Confo Therapeutics, CONTINUUS Pharmaceuticals, Convelo Therapeutics, Cooper-Vemedia, Cooper Companies, Cooper Surgical, Cormorant Pharmaceuticals, Cornell University, Corning, Cortexyme, Corvidia Therapeutics, Corvus Pharmaceuticals, Cosette Pharmaceuticals, COTA, COUR Pharmaceutical, Courtagen Life Sciences, COVAX, Covis Pharmaceutical, Crescendo Biologics, CRISPR Therapeutics, Crown Laboratories, CSL, CSL Behring, CSPC Pharmaceutical Group, CStone Pharmaceuticals, CTI BioPharma, Cue Biopharma, Cugene, Cumberland Pharmaceuticals, Curadev Pharma, Curadigm, Cure Duchenne, Cure Genetics, CureMatch, Cure Network Dolby Acceleration Partners, CureVac, CVC Capital Partners, Cyclenium Pharma, Cyclica, Cyon Therapeutics, Cypralis, Cystic Fibrosis Foundation, Cytel, CytomX Therapeutics, Cytoo, CytoReason, Cytovation, Daiichi Sankyo, Daiya, Dana-Farber Cancer Institute, Dare Bioscience, DarioHealth, DarwinHealth, Datavant, Datos Health, David H. Koch Institute for Integrative Cancer Research, Da Volterra, Day One Biopharmaceuticals, DayTwo, DEARhealth, Debiopharm, deCODE Genetics, Deerfield Management, Delinia, Delpharm, DelSiTech, Denali Therapeutics, Denovo Biopharma, Department of Defense, Department of Energy, Department of Health and Human Services, DepoMed, DePuy, Dermala, Dermavant Sciences, Dermira, Desma HC, Dewpoint Therapeutics, DexCom, Diaccurate, DiamiR, Diamond Light Source, Diannei Biotechnology, Diaprost, Diasend, DiCE Molecules, Dicerna Pharmaceuticals, Digital Therapeutics Alliance, DILIsym Services, Disability Solutions, Disarm Therapeutics, Disc Medicine, Distributed Bio, DJS Antibodies, DNX Biopharmaceuticals, doc.ai, Dogma Therapeutics, Domain Therapeutics, Dorizoe Lifesciences, Dr. Falk Pharma, Dr. Reddy's Laboratories, Dr. Susan Love Research Foundation, Dragonfly Therapeutics, Draper Laboratories, Drawbridge Health, Dren Bio, DRI Capital, Dual Therapeutics, Duchesnay, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Duke University, Dunad Therapeutics, Durect, Dyadic International, Dyno Therapeutics, Dystonia Medical Research Foundation, E-Scape Bio, Eagle Pharmaceuticals, EA Pharma, Easton Pharmaceuticals, Echosens, EDAP TMS, Eddingpharm, Edelris, Editas Medicine, EditForce, Edwards Lifesciences, eFFECTOR Therapeutics, Egalet, Egle Therapeutics, Eiger BioPharmaceuticals, EirGenix, Eisai, Eisai Inc, Eko, Elaaj Bio, Elanco, Elasmogen, Elektrofi, Eleven Biotherapeutics, Eligo Bioscience, Eli Lilly, Elix, Ellume, Elsevier, Embark Biotech, Emcure Pharmaceuticals, EMD Serono, Emendo Biotherapeutics, Emergent BioSolutions, Emirates Diabetes Society, Emory University, Empatica, Emulate, Enable Injections, Enamine, Enara Bio, Encore Dermatology, Engage Therapeutics, enGene, EnGeneIC, Engitix, EngMab, Enigma Biomedical, Enleofen Bio, Ensemble Therapeutics, Ensoma, Entegra Laboratories, Enteris Biopharma, Enterome Bioscience, Enterprise Therapeutics, Entos Pharmaceuticals, Envisagenics, Enzymatica, Enzyre, Enzyvant Science, EOC Pharma, EpiDestiny, Epigen Biosciences, Epilepsy Foundation (EF), EpiThany, Epivax, Epizyme, EPS International, Eracal Therapeutics, Erasca, Erasmus University Medical Center, ERP Biomarker Qualification Consortium, ERS Genomics, EspeRare Foundation, Esperion Therapeutics, ESSA Pharma, Essential Pharmaceuticals, Esteve, eTheRNA immunotherapies, Ethicon Endo-Surgery, ETH Zurich, Etubics, Eunice Kennedy Shriver Institute of Child Health and Human Development, Eureka Therapeutics, Eurofarma, Eurofins Discovery, European Commission, European Molecular Biology Laboratory, European Union, EUSA Pharma, EVA Pharma, Evaxion Biotech, Everest Medicines, Eversana, Evidation Health, Evogen, Evolve BioSystems, Evonik Industries, EVOQ Therapeutics, Evotec, Evox Therapeutics, Evozyne, Ewopharma, Exactis Innovation, Exact Sciences, Exagen Diagnostics, ExCEEd Orphan, Excelera Network, ExCellThera, Excelra, Exelead, Exelixis, Exicure, Exonate, Exopharm, Exosome Diagnostics, ExScientia, Eyegate Pharmaceuticals, Eyevance, F-Star, F-Star Therapeutics, Fabric Genomics, Facit, FairJourney Biologics, Fate Therapeutics, Fauna Bio, Feldan Therapeutics, Ferozsons Laboratories, Ferring Pharmaceuticals, Fibrogen, Fimbrion Therapeutics, Finch Therapeutics, FitBit, Five Prime Therapeutics, Flagship Biosciences, Flamma, Flatiron Health, Flowserve, FLX Bio, Flywheel, Foghorn Therapeutics, Food and Drug Administration (FDA), Forbius, Forendo Pharma, Forge Therapeutics, FORMA Therapeutics, ForSight VISION4, ForSight VISION5, Fortelinea Software Systems, Fortive, Fortress Biotech, Forty Seven, Forward Pharma, Fosun Pharmaceutical, Foundation Medicine, Fox Chase Cancer Center, Francis Crick Institute, Fraunhofer Institute for Molecular Ecology (IME), Frazier Healthcare Ventures, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, Freenome, French National Institute for Agricultural Research, Frequency Therapeutics, Fresenius Kabi Pharmaceuticals, Fresenius Medical Care, Frontage Clinical Services, Frontier Medicines, Fujifilm, Fujifilm Diosynth Biotechnologies, Fujifilm Kyowa Kirin Biologics, Fujirebio Diagnostics, Fulcrum Therapeutics, Fulgent Pharma, Fundacion Progreso y Salud, Fusion Genomics, Fusion Pharmaceuticals, G1 Therapeutics, G42 Healthcare, Gaia, Gain Therapeutics, Galapagos, Galderma, Galecto, Galvani Bioelectronics, Gamaleya National Center, GamaMabs Pharma, GammaDelta Therapeutics, Gan & Lee, Ganymed Pharmaceuticals, Gatehouse Bio, Gateway Hemophilia Association, GC Pharma, Gedeon Richter, GE Healthcare, Geisinger Health System, Geisinger Medical Center, Gemphire, Genea Biomedx, GeneCentric Therapeutics, GeneData, Genentech, Generate Biomedicines, Geneseeq, Genesis Therapeutics, Genestack, Genetic Leap, Genevant Sciences, Genexine, GenFleet Therapeutics, Genialis, Genmab, GenMark Diagnostics, Genocea Biosciences, Genome and Company, Genome Biologics, GenomeDx, Genomic Health, Genomics, genOway, Genpact, GenScript Biotech, GentiBio, Genzyme, Georgetown University, German Federal State Baden-Wurttemberg, German Government, Gero, Gilead Sciences, Ginkgo BioWorks, Glaxo Group, GlaxoSmithKline, GlaxoSmithKline Biologicals, Glenmark Pharmaceuticals, Global Antibiotic Research and Development Partnership, Global Blood Therapeutics, Global Coalition for Adaptive Research, Global Genomics Group, Global Health Innovative Technology Fund (GHIT), Global Lung Cancer Coalition, Global Stem Cell Technology, Glooko, GlucoMe, Glycotope Biotechnology, GlycoT Therapeutics, Glycyx Pharmaceuticals, Glympse Bio, GNA Biosolutions, GNS Healthcare, Goethe University Frankfurt, Goldfinch Bio, GoodRx, Good Start Genetics, Good Therapeutics, Google, Gossamer Bio, GO Therapeutics, Government of Canada, Government of France, Government of Japan, Government of Netherlands, Government of Singapore, Gowan Crop Protection, Gradalis, Grady Health System, Grail, Grand River Aseptic Manufacturing, Greenr U, Gritstone Bio, Grunenthal, Grupo Ferrer, GRYT Health, GSK Consumer Healthcare, GT Biopharma, Guangzhou Institute of Respiratory Disease, Guardant Health, Gubra, Gyroscope Therapeutics, H3 Biomedicine, Hackensack Meridian Health, Halix, Halozyme Therapeutics, Hamilton Thorne, HanaVax, Handl Therapeutics, Hanmi Pharmaceutical, Haplogen, Happify Health, HAPPYneuron, Harbour Biomed, Harm Reduction Therapeutics, Harpoon Therapeutics, Harrow Health, Harvard Medical School, Harvard Pilgrim Health Care, Harvard Stem Cell Institute, Harvard University, Hasten Biopharmaceutic, Headlands Research, Healis Therapeutics, Health2Sync, HealthCore, HealthPrize Technologies, HealthTab, Healx, Heartseed, Hebrew University of Jerusalem, Helsinn Healthcare, Hemophilia Foundation of Southern California, HemoShear, Hennepin County Medical Center, Hetero Labs, HiberCell, HiFiBio, Highlight Therapeutics, High Line Bio, Highmark Blue Shield, HighRes Biosolutions, Hikma Pharmaceuticals, HilleVax, Hillrom, Histogen, Hitachi Chemical, HitGen, HLS Therapeutics, Hoffmann La Roche, Holmusk, Holobiome, Homology Medicines, Honeywell, Hong Kong Science and Technology Parks, Hookipa Pharma, Hope Medicine, Horizon Discovery, Horizon Pharma plc, Horizon Therapeutics, Hospira, HotSpot Therapeutics, HP, Hsiri Therapeutics, HTG Molecular Diagnostics, Huma, Humana, Human Longevity, Hummingbird Bioscience, Hutchmed, Huyabio International, HUYA Bioscience, Hypera Pharma, I-mab, i2O Therapeutics, Ibex Medical Analytics, IBM, IBM Watson Health, Icagen, Icahn School of Medicine at Mount Sinai, Ichor Medical Systems, Icon, Iconic Therapeutics, ICU Medical, IDEAYA Biosciences, Idera Pharmaceuticals, Idorsia, IDT Biologika, Ieso Digital Health, IFM Therapeutics, IFM Tre, iGenomix, IGM Biosciences, IgniteData, IGNITE Immunotherapy, Ignyta, Ikena Oncology, Iktos, Illumina, ILTOO Pharma, ImageBiopsy Lab, ImaginAb, Imago Biosciences, Imbio, ImClone Systems, Imcyse, Immatics Biotechnologies, Immugenyx, Immune Biosolutions, Immune Deficiency Foundation, ImmuNext, Immunic, ImmunoBrain Checkpoint, Immunocore, ImmunoGen, Immunome, Immunomedics, ImmunoPrecise Antibodies, ImmunoQure, Immunovaccine, Immusoft, Immutep, ImmVira, Impax Laboratories, Imperial College London, Imperial Innovations, Imugene, IMV, INBRAIN Neuroelectronics, Inception Sciences, Incyte, Indiana Biosciences Research Institute, Indiana University, Industrial Technology Research Institute, Inex Innovation Exchange, Infex Therapeutics, Infinity Pharmaceuticals, Inflammasome Therapeutics, InflaRx, Inflazome, Inhalation Sciences, Inhibrx, Innate Pharma, INNERVIA Bioelectronics, Innodem Neurosciences, Innovate UK, Innovation Health, Innovation Network Corporation, Innovative Genomics Initiative (IGI), Innovative Medicines Initiative (IMI), Innovative Targeting Solutions, Innovent Biologics, Inotrem, Inovalon, iNova Pharmaceuticals, Inovio Pharmaceuticals, Inpixon, Insilico Biotechnology, Insilico Medicine, Insitro, Insmed Inc, Inspirion Delivery Sciences, Inspirna, Institut Curie, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for Systems Biology, Institute of Cancer Research, Institut Gustave Roussy, Institut Pasteur, Insud Pharma, Insulet, Intas Pharmaceuticals, Intec Pharma, Integral Molecular, Intel, Intellikine, Intensity Therapeutics, International Association for the Study of Lung Cancer, International Diabetes Federation (IDF), International Myeloma Foundation, International Process Plants, International Vaccine Institute (IVI), Intrexon, InveniAI, Invenio Imaging, Invenra, Inventiva, Invetx, Invitae, INVO Bioscience, InxMed, IO Biotech, IOmet Pharma, Ionian University, Ionis Pharmaceuticals, Ionova, IONTAS, Iota Biosciences, Iovance Biotherapeutics, iPharma, Ipsen, IQVIA, IRBM, Ironwood Pharmaceuticals, ISD Immunotech, iSTAR Medical, Italian Government, iTeos Therapeutics, Iterative Scopes, ITM Isotopen Technologien, Izana Bioscience, Jacobio Pharmaceuticals, Janssen-Cilag, Janssen Biotech, Janssen Human Microbiome Institute, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Sciences, Janssen Therapeutics, Janux Therapeutics, Japan Agency for Medical Research and Development, Japan Government, Japan Tobacco, Jasper Therapeutics, Javelin Biotech, Jazz Pharmaceuticals, JCR Pharmaceuticals, JDP Therapeutics, Jemincare, JenKem Technology, Jenner Institute, JHL Biotech, Jiangsu Chia Tai Tianqing Pharmaceutical, Jnana Therapeutics, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, Johnson & Johnson Vision, Jounce Therapeutics, Jubilant Biosys, Jubilant Life Sciences, Juno Therapeutics, Junshi Biosciences, Juventas Therapeutics, Juvise Pharmaceuticals, Kadmon Pharmaceuticals, KAHR Medical, Kaiku Health, Kaken Pharmaceutical, Kaleido Biosciences, KaliVir Immunotherapeutics, Kallyope, KalVista Pharmaceuticals, Kamada, KaNDy Therapeutics, Karolinska Institute, Karyopharm Therapeutics, Kedalion Therapeutics, Keio Gijuku University, Kelun-Biotech Biopharmaceutical, KeyBioScience, Kiadis Pharma, Kindeva Drug Delivery, Kineta, Kings College London, Kiniksa Pharmaceuticals, Kissei Pharmaceutical, Kit Check, Kite Pharma, Klaria, Kneat, Knight Therapeutics, Kolon Life Science, Koneksa Health, Kowa Pharmaceuticals America, Kramer Laboratories, Kronos Bio, KSQ Therapeutics, KTH Royal Institute of Technology, Kumquat Biosciences, Kunming Wuhua Healthcare Hospital, Kura Oncology, Kymab, Kymera Therapeutics, Kyn Therapeutics, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kyowa Hakko Kirin Pharmaceuticals, Kyttaro, Kyverna Therapeutics, L'Oreal, LabCentral, Labcyte, Laboratoires DELBERT, Labor Dr. Merk & Kollegen, Lacerta Therapeutics, Laekna, Lannett, Lava Therapeutics, Lazada Group, Lazarex Cancer Foundation, Lead Discovery Center, Lead Pharma, Leap Therapeutics, Le Bonheur Children's Hospital, Lee Moffitt Cancer Center, Legend Biotech, LegoChem Biosciences, Leicester University, Leiden University, Leidos, Leon-nanodrugs, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, Lexicon Pharmaceuticals, LFB Biotechnologies, LFB Group, LianBio, Lieber Institute, LifeArc, Lifebit Biotech, LifeCell, LifeLabs Medical Laboratory Services, LifeMax Laboratories, LifeMine Therapeutics, Life Raft Group, Ligand Pharmaceuticals, Light Chain Bioscience, Lilly Endowment, Lilly Institute for Genetic Medicine, Lineage Cell Therapeutics, Linnaeus Therapeutics, Lipidomics Consulting, Lipigon Pharmaceuticals, Litesprite, Livongo Health, LLamasoft, Locus Biosciences, Lodo Therapeutics, LogicBio Therapeutics, Lonza, LOTTE, Loulou Foundation, Loxo Oncology, LTL Pharma, Lubris BioPharma, LUCA Science, Lumen Biomedical, Luminex, Luminostics, Lumos Pharma, Lundbeck, Lund University, Lung Cancer Initiative, Lung Cancer Research Foundation, Lupin, Lupin Limited, Lupin Pharmaceuticals, Lupus Research Alliance, Lupus Therapeutics, Luxna Biotech, Luye Pharma Group, Lycia Therapeutics, Lyell Immunopharma, Lyfebulb, Lyndra Therapeutics, Lyvgen Biopharma, M2Gen, Mabion, MabVax Therapeutics, mAbXience, Macrogenics, Magellan Health Services, Magenta Therapeutics, Mammoth Biosciences, Mapi Pharma, Marinus Pharmaceuticals, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, MassBio, MaSTherCell, Matrix Medical Network, Maverick Therapeutics, Max-Planck, Max Foundation, Maxor National Pharmacy, Mayne Pharma, Mayo Clinic, MC10, McGill University, McKesson, McNeil Consumer Pharmaceuticals, McQuade Center for Strategic Research and Development, MD Anderson Cancer Center, Mectizan Donation Program, Medac, Medgenics, Medial EarlySign, Medibio, Medicago, Medical Developments International, Medical Research Council, Medical Research Foundation, Medicenna Therapeutics, Medicines360, Medicines Development for Global Health, Medicines Patent Pool Foundation, Medicure, Medidata Solutions, Medimetriks, MedImmune, Medipal Holdings, MediSafe, Medivation, Medivir, MedRhythms, Medtronic, Meiji Seika, Meiogenix, MEI Pharma, MeiraGTx, Melinta Therapeutics, MEME, Memorial Sloan Kettering Cancer Center, Menarini, Menarini Asia-Pacific, Menicon, Mentor, Merck and Co, Merck Animal Health, Merck Company Foundation, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Meridian Bioscience, Merrimack Pharmaceuticals, Mersana Therapeutics, Merus, Merus Labs International, Merz, Mesoblast, Metabolon, Metacrine, Metastatic Breast Cancer Network, METAvivor, Michael J Fox Foundation, Microbiotica, MicroHealth, Microsoft, MILA International, Millendo Therapeutics, Millennium, MilliporeSigma, Milner Therapeutics Institute and Consortium, Mimetas, MiNA Therapeutics, MiNDERA, MindImmune Therapeutics, Mindstrong Health, Ministry of Health (Denmark), Ministry of Health, Labor and Welfare, Ministry of Health and Prevention, Minovia Therapeutics, Mirati Therapeutics, miRecule, Mirimus, MiroBio, Miromatrix Medical, Mirum Pharmaceuticals, MiRXES, Mission Therapeutics, MiTest Health, Mitobridge, Mitokinin, Mitsubishi Tanabe Pharma, Moberg Pharma, MOBILion Systems, Modag, Moderna, Moebius Medical, Molecular Partners, Molecular Stethoscope, Molecular Templates, Molecular You, Mologen, Momenta Pharmaceuticals, Monash University, Monsanto, MoonLake Immunotherapeutics, Morehouse School of Medicine, Morningside Ventures, Morphic Therapeutic, MorphoSys, Motus Therapeutics, Mount Sinai Health System, MSD, MSN Pharmaceuticals, Multiple Sclerosis Society of Canada, Mundipharma, MustGrow Biologics, My Brother’s Keeper, Myeloma UK, Mylan Laboratories, Mylan Pharmaceuticals, Mymetics, MyoKardia, Myovant Sciences, Myriad Genetics, Myriad RBM, MYR Pharma, Myrtelle, Nabriva Therapeutics, Nanoform, NanoString Technologies, NantKwest, NantWorks, NapaJen Pharma, Narayana Nethralaya Foundation, Nashville Biosciences, National Academy of Sciences, National Cancer Center, National Cancer Institute, National Center for Cardiovascular Diseases, National Comprehensive Cancer Network (NCCN), National Eye Institute, National Healthcare Services (NHS), National Health Service, National Heart, Lung and Blood Institute, National Human Genome Research Institute, National Institute for Innovation in Manufacturing Biopharmaceuticals, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Infectious Diseases, National Institute of Mental Health, National Institute of Molecular Genetics, National Institute of Neurological Disorders and Stroke, National Institute on Deafness and Other Communication Disorders, National Institute on Drug Abuse (NIDA), National Institutes of Biomedical Innovation, Health and Nutrition, National Institutes of Health, National Newspaper Publishers Association, National Organization for Rare Disorders, National Research Council Canada, National Resilience, National Surgical Adjuvant Breast and Bowel Project, Natrix Separations, NBE Therapeutics, Ncardia, Nectin Therapeutics, Nektar Therapeutics, Nemaura Pharma, Neogene Therapeutics, Neogenomics, NeoImmuneTech, Neoleukin Therapeutics, NeoMed, Neon Therapeutics, Neos Therapeutics, Nerviano Medical Sciences, Nestle, NETRIS Pharma, NetVation DL Medicine, NeuBase Therapeutics, Neumentum, Neumora Therapeutics, Neuraxpharm, Neurimmune Therapeutics, Neurocrine Biosciences, NeuroCycle Therapeutics, NeuroDerm, NeuroMetrix, Neuronetics, Neuronetrix, NeuroSigma, NeuroTracker, Neurovance, NeuroVision Imaging, NewAmsterdam Pharma, New Brunswick Health Research Foundation, New Ruipeng Group, New York Genome Center (NYGC), Nexelis, NextCure, Nference, NGM Biopharmaceuticals, NiKang Therapeutics, Nimble Therapeutics, Nimbus Apollo, Nimbus Therapeutics, Ningbo NewBay Medical Technology, Ningbo Tai Kang Medical Technology, Nitto Denko, NKGen Biotech, NKMax America, NLS Pharmaceutics, Noema Pharma, Noile-Immune Biotech, Noom, Nordic Bioscience, Norgine, Noria Therapeutics, Northern Biologics, Northern California Institute for Research and Education, Northwestern University, Nouscom, Novadiscovery, NovAliX, Novartis, Novartis Institute for Tropical Diseases, Novartis Institutes for BioMedical Research, Novartis Pharmaceuticals Canada, Novavax, NovImmune, Novocure, Novoheart, Novome Biotechnologies, Novo Nordisk, Novozymes, Noxopharm, Noxxon Pharma, Nrgene, NuBiyota, Nucleai, Nuevolution, Numab, Numerate, Nurix, Nutritional Growth Solutions, Nuvelution Pharma, Nuviant Medical, NuvoAir, NWO.ai, Nxstage Medical, NXT Biomedical, Nykode Therapeutics, Nymirum, Oak Hill Bio, OARO, Obsidian Therapeutics, Ochsner Health System, Octagon Research Solutions, Octapharma, Ocular Therapeutix, Oculis, Ogeda, Ohio State University, OKKO Health, Oklahoma Health Care Authority, Oklahoma Medical Research Foundation, Olema Oncology, Omada Health, Onco360, Oncode Institute, Oncodesign, Oncoheroes Biosciences, OncoImmune, Oncologie, Oncology Venture, Oncolytics Biotech, OncoSec Medical, Oncoshot, One Drop, OneOncology, oNKo-innate, OnKure, Ono Pharmaceutical, Ontario Institute for Cancer Research, OpGen, Ophirex, Opiant Pharmaceuticals, OPKO Health, Optellum, Optibrium, Optum, Oracle Health Sciences, Orchard Therapeutics, Orexigen Therapeutics, Organon, ORIC Pharmaceuticals, Orifarm, OrigiMed, Origimm Biotechnology, Orion, Orionis Biosciences, Orna Therapeutics, Orsini Healthcare Specialty Pharmacy, OrsoBio, Osaka University, OSE Immunotherapeutics, OSI Pharmaceuticals, Oslo University Hospital, Ossianix, Otsuka, Otsuka America Pharmaceutical, Outpost Medicine, Ovensa, Ovid Therapeutics, Owkin, Owlstone Medical, Oxford Biodynamics, Oxford BioMedica, Oxford BioTherapeutics, Oyster Point Pharma, P-Chip, Padlock Therapeutics, Paige, Palantir, panCELLa, Pandion Therapeutics, Pantherna Therapeutics, PANTHERx Specialty Pharmacy, Parexel, Parkinson's Institute and Clinical Center, Parkinsons Disease Foundation, Partner Therapeutics, Parvus Therapeutics, PathAI, Patheon, PatientFi, PatientsLikeMe, PDL BioPharma, PDS Biotechnology, PEAR Therapeutics, PegBio, Peking University, Peloton Therapeutics, Pendopharm, Pennsylvania Biotechnology Center, PeptiDream, Perception Neuroscience, PerkinElmer, Perlara, Perrigo, Persephone Biosciences, Personal Genome Diagnostics, Personalis, Perthera, PetaGene, Petra Pharma, Pfizer, Pfizer Canada, Pfizer Japan, Phanes Therapeutics, PharmAbcine, PharmaEngine, PharmaIN, PharmaMar, Pharmaron, Pharming Group, PhaseBio Pharmaceuticals, Phathom Pharmaceuticals, Pheno Therapeutics, Phillips-Medisize, Philogen, Phlexglobal, Phoenix Molecular Designs, PhoreMost, PicnicHealth, Pieris Pharmaceuticals, Pierre Fabre, Pilloxa

For a full list please contact us on orders@currentpartnering.com

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.